

Remarks/Arguments


Applicants have amended the specification to incorporate the priority claim.

The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Thus, claims 1, 14, 19, 20, 21, 22, and 23 are as originally presented. Claims 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, and 18 are currently amended. Claims 16 and 17 are cancelled. No new matter has been added by these amendments. Also, the above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application. Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No.

50-3231, referencing Attorney Docket No. 100856.

Respectfully submitted,



Name: Heidi Berven
Dated: May 28, 2005
Reg. No.: 48,951
Phone No.: 781-839-4336
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760